Bringing you the latest Business News updates from the science industry
by Heather Hobbs Priorclave Celebrates 25th Anniversary
British autoclave manufacturer Priorclave is celebrating 25 years since first opening its doors for business on the 16th February 1988, a time- span during which almost 5,000 steam sterilisers have been delivered from its London factory worldwide.
Founder and Chairman Charles Prior is a firm believer that in Britain we have the most talented engineering capabilities and this is reflected in the fact that all autoclaves leaving the Priorclave factory are of British design and manufacture. With firmly established markets in the UK, exports account for around 70% of business with destinations including Asia Pacific, the Middle East as well as North and South America, an endorsement of the quality and reliability of these products, the company said. Some notable countries and contract wins where Priorclave steam sterilisers have been installed include Russia, Papua New Guinea, Mauritius and Ecuador.
Over the 25 years the Company’s dedicated design and manufacturing centre has created one of the largest ranges of standard steam sterilisers, from compact bench-top front loading to free-standing top- loading and high capacity front-loading autoclaves as well as power
door and pass-through double entry machines. It is unlikely, the company claimed, that customers cannot find a model to meet their needs particularly as Priorclave can incorporate many of its optional items into even the smallest machines at its London factory, unlike other autoclave suppliers where many options only exist on the larger sterilisers.
Describing Priorclaves visually as something akin to ‘shiny, sophisticated ovens or fridges, with some pretty lights’ Charles Prior also underlined the importance of this apparatus by also describing them as ‘also a bit like a Tornado or Typhoon fighter plane – smooth, clean and attractive lines, but underneath a deceptively vicious killing machine – the victims this time being bacteria and viruses.’
Buying a Priorclave he continued, could be seen by the customer as a wise investment since it offers the lower overall cost of ownership through highly efficient performance with a first-rate pre- and after-sales support and backed by one of the best warranties currently available. Priorclave also provides excellent and dedicated on-going support to ensure the autoclave delivers the ultimate sterilising process, he added.
AstraZeneca to Invest in Strategic R&D Centres in the UK, Sweden and US
AstraZeneca has announced plans to invest in strategic research and development centres in the UK, the US and Sweden to improve pipeline productivity and to establish the company as a global leader in biopharmaceutical innovation. The proposals are designed to:
• Locate more of the company’s scientists close to globally recognised bioscience clusters, making it easier to access world- class talent and opportunities for collaboration and partnerships;
• Bring teams together to improve collaboration and to create a more vibrant environment that puts science and the patient at the heart of everything the company does;
• Simplify the company’s footprint to reduce complexity and eliminate unnecessary cost.
Under the plans, AstraZeneca’s small molecule and biologics R&D activities will be concentrated in three strategic centres: Cambridge, UK; Gaithersburg, US; Mölndal, Sweden. The proposals are expected to be fully implemented by 2016.
Globally, over the 2013-2016 period, the proposed investment and associated changes will lead to the relocation of nearly 2,500 roles and an overall estimated reduction in headcount in the region of 1,600 roles. The vast majority of these will be in the UK and the US. The programme is expected to incur $1.4 billion in one-time restructuring charges, of which $800 million are likely to be cash costs. In addition, the company will invest approximately $500 million in establishing the new centre in Cambridge. Annualised benefits of approximately $190 million are expected by 2016.
MORE INFO. 57 Verder Scientific Division Looks to Global Expansion
The Dutch technology group Verder has strengthened its international business activities with the expansion of its product portfolio to include high-temperature material testing and physiochemical analysis.
The Verder Group consists of two main business units - Liquids (positive displacement pumps) and Scientific (laboratory equipment). With more than 800 employees and subsidiaries in 19 countries the group generates an annual turnover of €160 million. The core of the Scientific Division which has been built on renowned companies such as Retsch and Retsch Technology has now been extended by Endecotts Ltd., Eltra GmbH and Carbolite Ltd Dr Juergen Pankratz was appointed Director of the Verder Scientific Division.
Eltra, now located under the same roof as Retsch in Germany, is specialised in elemental analysis of organic and inorganic materials such as coal and steel. Carbolite is a leading manufacturer of high-temperature furnaces for a variety of applications in industrial laboratories as well as in science and R&D. Uniting the companies under the umbrella of Verder Scientific produces synergetic effects for all parties. These latest acquisitions have consolidated the Verder Group’s position as a leading supplier of system solutions for sample preparation and analysis of solids. The group provides a global network of subsidiaries offering competent customer support.
Dr Juergen Pankratz MORE INFO. 58
Founder and Chairman Charles Prior MORE INFO. 56
Pivot Park and Spinnovation Analytical Join forces
Spinnovation Analytical BV is to supply analytical services to the newly established Pivot Park Life Sciences Community (The Netherlands) located on the former Organon/Schering Plough/MSD research site in Oss. The park is a centre for open-innovation, where facilities, instruments and knowledge are made available to the pharmaceutical and biotech companies based on the site.
Spinnovation will support small-molecule pharmaceutical and the biopharmaceutical industries through its portfolio of analytical services for medicinal chemists focused on discovery programs and pre-clinical development, as well as those of Contract Manufacturing Organisations (CMOs), by supporting Chemistry Manufacturing Control (CMC) activities. Spinnovation will add to the platform at Pivot Park by providing 500MHz NMR, ESI-TOF MS, HPLCs, LC- SPE and ICP-OES instruments.
The advanced facilities available at Pivot Park will also help Spinnovation to further strengthen and develop Spinnovation Biologics, a service offered to the European and US biopharmaceutical industry dedicated to the support of upstream process development.
“We are very excited to welcome Spinnovation who will facilitate access to advanced analytical applications for the Pivot Park tenants,” commented Alie Tigchelhoff, Director of Pivot Park. “We have full confidence that Spinnovation’s exceptional analytical solutions will support the growth of our companies and the spirit of research and development which the park has been designed for.”
Frederic Girard, CEO of Spinnovation Analytical, said, “We are very pleased to be collaborating with Pivot Park and its members. We look forward to contributing to the success of the park and the exciting ventures and projects of its members through providing access to our unique range of solutions and expertise, as well as developing the unique services provided by Spinnovation Biologics.”
MORE INFO. 59
To be included in our next issue, send all your Business and Financial News stories to
heather@intlabmate.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68
